Literature DB >> 12741480

Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome.

Abhinandana Anantharaju1, Mehdi Baluch, David H Van Thiel.   

Abstract

Transverse myelitis (TM) as a manifestation of an autoimmune disorder is relatively rare. In Sjogren's syndrome (SS), the occurrence of TM is remarkably uncommon. Only three cases have been reported associated with primary biliary cirrhosis (PBC). Here we report the fourth case of TM occurring in association with SS and PBC. Patients with unexplained transverse myelitis require a careful search for an underlying etiology to include the findings of SS and PBC. The precise pathogenesis of TM in patients with SS is unknown. Most show good response to steroids. Cyclophosphamide and chlorambucil may be useful in those who respond poorly to steroids.

Entities:  

Mesh:

Year:  2003        PMID: 12741480     DOI: 10.1023/a:1022821800714

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

Review 1.  Sjögren's syndrome associated with liver and neurological disorders, and malignant lymphoma.

Authors:  S Sugai
Journal:  Intern Med       Date:  2000-03       Impact factor: 1.271

2.  Sjögren's syndrome with primary biliary cirrhosis, complicated by transverse myelitis and malignant lymphoma.

Authors:  T Wakatsuki; M Miyata; S Shishido; T Suzuki; H Ohira; M Kokubun; Y Sato; T Yamamoto; R Kasukawa
Journal:  Intern Med       Date:  2000-03       Impact factor: 1.271

3.  Sjögren's syndrome with acute transverse myelopathy as the initial manifestation.

Authors:  Y Manabe; C Sasaki; H Warita; T Hayashi; Y Shiro; K Sakai; K Kashihara; K Abe
Journal:  J Neurol Sci       Date:  2000-06-15       Impact factor: 3.181

Review 4.  [A case of primary Sjögren's syndrome with acute transverse myelopathy and polyneuropathy as the initial manifestations].

Authors:  C Yanagihara; K Nakaji; Y Nishimura
Journal:  Rinsho Shinkeigaku       Date:  2001-01

5.  Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.

Authors:  C Vitali; S Bombardieri; H M Moutsopoulos; J Coll; R Gerli; P Y Hatron; L Kater; Y T Konttinen; R Manthorpe; O Meyer; M Mosca; P Ostuni; R A Pellerito; Y Pennec; S R Porter; A Richards; B Sauvezie; M Schiødt; M Sciuto; Y Shoenfeld; F N Skopouli; J S Smolen; F Soromenho; M Tishler; M J Wattiaux
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

6.  Primary biliary cirrhosis, Sjogren's syndrome, and transverse myelitis.

Authors:  G Rutan; A J Martinez; J T Fieshko; D H Van Thiel
Journal:  Gastroenterology       Date:  1986-01       Impact factor: 22.682

7.  Antineuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome.

Authors:  J W Moll; H M Markusse; J J Pijnenburg; C J Vecht; S C Henzen-Logmans
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

Review 8.  Treatment of myelopathy in Sjögren syndrome with a combination of prednisone and cyclophosphamide.

Authors:  C S Williams; E Butler; G C Román
Journal:  Arch Neurol       Date:  2001-05

9.  [A case of Sjögren's syndrome with rheumatoid arthritis manifesting transverse myelitis with antineuronal antibody].

Authors:  Y Fujimoto; S Arai; K Ishida; T Yokota; M Yaginuma; H Murase
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1995-02

10.  Subclinical multisystemic autoimmunity presenting as a progressive myelopathy.

Authors:  G Linardaki; F N Skopouli; C Koufos; H M Moutsopoulos
Journal:  Lupus       Date:  1997       Impact factor: 2.911

  10 in total
  2 in total

1.  Longitudinal extensive transverse myelitis: a rare neurological complication of systemic lupus erythematosus.

Authors:  Sara Seyedali; Deborah R Alpert
Journal:  BMJ Case Rep       Date:  2019-04-25

Review 2.  Demyelination in rheumatic diseases.

Authors:  A Theodoridou; L Settas
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.